Recent test studies have shown that experimental breast cancer drugs from Pfizer Inc. (NYSE:PFE) have the capacity to slow or halt the progression of advanced tumors. This should be a great addition as a form of treatment, for patients suffering from both conditions while also adding to the top therapies in the industry. Pfizer Inc. (NYSE:PFE) shares after opening at $29.97 moved to $30.15 on last trade day and at the end of the day closed at $29.89. Company price to sales ratio in past twelve months was calculated as 3.70 and price to cash ratio as 5.90. Pfizer Inc. (NYSE:PFE) showed a negative weekly performance of -3.17%.
A turnaround in Johnson & Johnson (NYSE:JNJ) prescription medicine business fuelled by new drugs, combined with reduced production and administration expenses, lifted first-quarter profit by 8 percent. Johnson & Johnson (NYSE:JNJ) shares advanced 2.12% in last trading session and ended the day on $99.20. JNJ return on equity ratio is recorded as 19.70% and its return on assets is 10.90%. Johnson & Johnson (NYSE:JNJ) yearly performance is 22.39%.
Bristol-Myers Squibb Co. (NYSE:BMY) announced the submission of a new drug application (NDA) to the U.S. Food and Drug Administration (FDA) for a fixed-dose combination of atazanavir sulfate, a protease inhibitor marketed as Reyataz, and cobicistat, an investigational pharmacokinetic enhancer, or boosting agent, that can increase the level of certain HIV-1 medicines in the blood and make them more effective. Bristol-Myers Squibb Co (NYSE:BMY) shares moved up 0.44% in last trading session and was closed at $48.17, while trading in range of $47.48 – $48.48. Bristol-Myers Squibb Co (NYSE:BMY) year to date (YTD) performance is -8.73%.
Merck & Co. Inc. (NYSE:MRK) says the Food and Drug Administration has approved its new tablet for grass allergies, Grastek, for patients five to 65 years old. Merck & Co., Inc. (NYSE:MRK) weekly performance is 1.84%. On last trading day company shares ended up $56.05. Merck & Co., Inc. (NYSE:MRK) distance from 50-day simple moving average (SMA50) is 0.94%. Analysts mean target price for the company is $57.11.
Leave a Reply